open access

Vol 49, No 4 (2018)
Original Research Article/Praca Oryginalna
Published online: 2018-12-31
Submitted: 2018-11-25
Get Citation

Nivolumab for relapsed/refractory classical Hodgkin lymphoma after brentuximab vedotin failure – Polish Lymphoma Research Group real-life experience

Monika Długosz-Danecka, Michał Szymczyk, Joanna Fischer, Anna Łojko-Dankowska, Justyna Rybka, Joanna Mańko, Katarzyna Duda, Wojciech Jurczak
DOI: 10.2478/ahp-2018-0026
·
Acta Haematol Pol 2018;49(4):228-233.

open access

Vol 49, No 4 (2018)
Original Research Article/Praca Oryginalna
Published online: 2018-12-31
Submitted: 2018-11-25

Abstract

Aim

Polish centers analyzed retrospectively the real-life experience with nivolumab in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) patients, after brentuximab vedotin (BV ) failure.

Background

Despite the effective frontline treatment, for cHL patients relapsing after autologous stem cell transplantation, the only effective strategy remains the novel agents. Nivolumab, a checkpoint inhibitor, demonstrates the clinical benefit with an acceptable safety profile.

Materials and methods

Retrospective analysis included 16 adult patients with R/R cHL after BV failure. All patients received single-agent nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity.

Results

After six cycles of nivolumab the overall response rate was 81% (complete remission rate of 56%, partial remission rate of 25%). The median PFS was not reached after a median follow-up of 19 months. Adverse events (AEs) of any grade occurred in 12 patients (75%), including grade 3 AEs observed in 5 patients (31%). There were no AEs of grade 4 or 5. After a median of 25 nivolumab doses, 62% of responding patients proceeded to allogeneic stem cell transplantation.

Conclusion

Nivolumab monotherapy demonstrated a high efficacy and safety in R/R cHL patients after BV failure. More patients and longer follow-up may further establish the potential benefit.

Abstract

Aim

Polish centers analyzed retrospectively the real-life experience with nivolumab in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) patients, after brentuximab vedotin (BV ) failure.

Background

Despite the effective frontline treatment, for cHL patients relapsing after autologous stem cell transplantation, the only effective strategy remains the novel agents. Nivolumab, a checkpoint inhibitor, demonstrates the clinical benefit with an acceptable safety profile.

Materials and methods

Retrospective analysis included 16 adult patients with R/R cHL after BV failure. All patients received single-agent nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity.

Results

After six cycles of nivolumab the overall response rate was 81% (complete remission rate of 56%, partial remission rate of 25%). The median PFS was not reached after a median follow-up of 19 months. Adverse events (AEs) of any grade occurred in 12 patients (75%), including grade 3 AEs observed in 5 patients (31%). There were no AEs of grade 4 or 5. After a median of 25 nivolumab doses, 62% of responding patients proceeded to allogeneic stem cell transplantation.

Conclusion

Nivolumab monotherapy demonstrated a high efficacy and safety in R/R cHL patients after BV failure. More patients and longer follow-up may further establish the potential benefit.

Get Citation

Keywords

checkpoint inhibitor; Hodgkin Lymphoma; nivolumab, refractory; relapsed

About this article
Title

Nivolumab for relapsed/refractory classical Hodgkin lymphoma after brentuximab vedotin failure – Polish Lymphoma Research Group real-life experience

Journal

Acta Haematologica Polonica

Issue

Vol 49, No 4 (2018)

Pages

228-233

Published online

2018-12-31

DOI

10.2478/ahp-2018-0026

Bibliographic record

Acta Haematol Pol 2018;49(4):228-233.

Keywords

checkpoint inhibitor
Hodgkin Lymphoma
nivolumab
refractory
relapsed

Authors

Monika Długosz-Danecka
Michał Szymczyk
Joanna Fischer
Anna Łojko-Dankowska
Justyna Rybka
Joanna Mańko
Katarzyna Duda
Wojciech Jurczak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl